Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.本發明提供一種對鈉依賴性葡萄糖協同轉運蛋白SGLT2具有抑制效果之結晶型化合物。本發明還提供醫藥組合物、製備該結晶型化合物的方法,及獨立地或與其他治療劑結合使用該結晶型化合物以治療受SGLT或SGLT2抑制影響之疾病或病症的方法。